December 12, 2005 -- Myogen rose more than 40% after ambrisenta helped people suffering from pulmonary arterial hypertension; the news hurt competing companies including Actelion, Encysive and Pfizer; Merck was lower after a Federal Judge declared a mistrial in a Vioxx case; Pain Therapeutics stopped a test of PTI-901 for irritable bowel syndrome; MedImmune said a new version of its inhaled FluMist outperformed an injection; DOV Pharmaceutical released positive interim data from a pain drug trial tive; and the FDA reported possible side effect problems with an Abbott Labs antibiotic, Biaxin. Biotech closed lower, with the Centient Biotech 200™ dropping 8 points to end at 3976.75, a loss of .20%. More details...
